Non-interventional Study Exploring the Composition of the Valvular Microbiota of Patients Undergoing Cardiac Surgery

NCT ID: NCT07075601

Last Updated: 2025-07-20

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Clinical Phase

NA

Total Enrollment

200 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-08-01

Study Completion Date

2029-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The prevalence of aortic valve disease is increasing, with these valvulopathies present in half of individuals over the age of 65.

Oberbach A. et al (1) demonstrated the presence of microbiota in 52% of cases of explanted aortic valves. One current hypothesis is the role of this microbiota in the pathophysiology of these degenerative valve diseases. This microbiota is probably not completely eradicated after resection of the native valve and implantation of a conventional prosthesis; it is even left in place during percutaneous aortic valve implantation, during which the prosthesis is deployed within the native valve. It could therefore also play a role in the occurrence of postoperative complications and the degeneration or thrombosis of a bioprosthesis.

Furthermore, recent clinical and epidemiological studies have shown a link between oral infections and cardiovascular diseases. As recommended by the HAS, these patients require multidisciplinary care, involving cardiologists, cardiac surgeons and general practitioners, as well as careful oral and dental care and monitoring provided by specialists in oral pathologies and oral care. The accumulation of bacterial plaque on the surface of the tooth and certain oral bacteria causes the development of periodontal pockets which are characteristic of periodontitis. Bacteria, microbial products and inflammatory mediators produced locally can then enter the bloodstream and affect distant organs such as the cardiovascular system. The recommendations of the European Society of Cardiology are therefore to carry out regular oral and dental consultations to prevent the risk of infection. Therefore, within the Toulouse University Hospital, a care network has been set up for patients with cardiovascular pathologies, in order to improve their access to dental care, screening and management of oral diseases. For the past year, patients hospitalized in the cardiology departments have been seen in consultation in the dental department of the Toulouse University Hospital.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Valvulopathy Cardiac Surgery Microbiota

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

PREVENTION

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Patients with an indication for cardiac surgery

Patients with an indication for cardiac surgery during which the aortic valve is explanted.

Group Type EXPERIMENTAL

Take 1 ml of blood

Intervention Type BIOLOGICAL

Take 1 ml of blood

DNA sequencing

Intervention Type BIOLOGICAL

DNA sequencing

Valve collection (healthcare waste)

Intervention Type PROCEDURE

Valve collection (healthcare waste)

Collection of serious post-operative complications

Intervention Type OTHER

Collection of serious post-operative complications

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Take 1 ml of blood

Take 1 ml of blood

Intervention Type BIOLOGICAL

DNA sequencing

DNA sequencing

Intervention Type BIOLOGICAL

Valve collection (healthcare waste)

Valve collection (healthcare waste)

Intervention Type PROCEDURE

Collection of serious post-operative complications

Collection of serious post-operative complications

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male or female patient.
* Present an indication for cardiac surgery that requires explantation of the aortic valve.
* Be able to receive information about the study process and understand the study participation information form.
* State their non-opposition to participating in the study.

Exclusion Criteria

* Patients infected with HIV
* Age under 18
* Under court supervision, guardianship, or curatorship
* Patients with a history of infective endocarditis.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University Hospital, Toulouse

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Rangueil Hospital

Toulouse, France, France

Site Status

Countries

Review the countries where the study has at least one active or historical site.

France

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Bertrand MARCHEIX, MD

Role: CONTACT

5 61 32 37 18 ext. +33

Audrey TOMASIK

Role: CONTACT

5 61 77 85 97 ext. +33

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Bertrand MARCHEIX, MD

Role: primary

561323718 ext. +33

Audrey TOMASIK

Role: backup

5 61 77 85 97 ext. +33

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2025-A00422-47

Identifier Type: OTHER

Identifier Source: secondary_id

RC31/25/0020

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.